InDex Pharmaceuticals updates timeline for top line results from the CONDUCT study to first half of 2019

InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the drug candidate cobitolimod. Top line results from the study are now expected in the first half of 2019 instead of in the fourth quarter of 2018 as previously communicated.

AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program

US patent granted for Tumorad®

Spago Nanomedical AB (publ) announce today that the United States Patent and Trademark Office (USPTO) has granted the company´s patent application comprising product protection for Tumorad® in the USA.

AbbVie and Calico Announce Extension of Groundbreaking Collaboration

Extension builds on collaboration established in 2014. Collaboration focuses on aging and age-related diseases, including neurodegeneration and cancer.

AbbVie and Calibr announce collaboration for next generation T-cell therapies

Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors